Detalhe da pesquisa
1.
Anti-programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study.
Eur J Cancer
; 160: 134-139, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34810048
2.
The letter responds to comment on: Anti-PD(L)1 immunotherapies in patients with cancer and with pre-existing systemic sclerosis: a post-marketed safety assessment study.
Eur J Cancer
; 165: 208-209, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35236567